NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

(NYSE MKT:NRXS), CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced new medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing approximately 566,000 total covered lives, in […]

Kawasaki Engines to Launch New Technical Training Center for Dealers

GRAND RAPIDS, Mich., Nov. 12, 2025 (GLOBE NEWSWIRE) — Kawasaki Engines is proud to announce the upcoming grand opening of its new Technical Training Center, designed to deliver a more advanced and immersive educational experience to its dealer network. Scheduled to open in January 2026 at division headquarters in Grand Rapids, Mich., the state-of-the-art facility

Titan Aviation Leasing Completes Sale of Two Boeing 737-800SF Aircraft to ST Engineering

DUBLIN, Nov. 12, 2025 (GLOBE NEWSWIRE) — Titan Aviation Leasing (“Titan”), the joint venture between Titan Aviation Holdings, Inc. (a subsidiary of Atlas Air Worldwide) and Bain Capital, today announced the sale of two Boeing 737-800SF aircraft to ST Engineering, a leading global technology, defense and engineering group headquartered in Singapore. The aircraft are currently

Acres Partners with Urban Land Institute to Advance Land and Housing Research

Fayetteville, Ark., Nov. 12, 2025 (GLOBE NEWSWIRE) — Acres.com, the complete land intelligence platform, has partnered with Urban Land Institute Northwest Arkansas to strengthen housing and land-use research in one of the nation's fastest-growing regions. The collaboration will provide ULI NWA with access to Acres' national parcel and ownership data, supporting regional planning and development

GigaCloud Technology Inc. to Participate in 14th Annual Roth Technology Conference on November 19

(NasdaqGM:GCT), EL MONTE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — GigaCloud Technology Inc (Nasdaq: GCT) (“GigaCloud” or the “Company”), a pioneer of global end-to-end B2B technology solutions for large parcel merchandise, today announced that Iman Schrock, its President, and Erica Wei, its Chief Financial Officer, will participate in the 14th Annual Roth Technology Conference on

WedWallet(TM) Soft Launches to Redefine Trust in Wedding Payments

WedWallet(TM) Soft Launches to Redefine Trust in Wedding Payments 90% of wedding payments today aren't fully compliant – WedWallet aims to change that GlobeNewswire November 12, 2025 SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) — The U.S. wedding industry moves over $70 billion each year, yet more than 90% of those payments aren't handled fully

Aqua-Tots Swim School to Make a Splash in Strongsville This Winter

Strongsville, Ohio, Nov. 12, 2025 (GLOBE NEWSWIRE) — Aqua-Tots Swim School, the largest international swim school franchise, is preparing to open its newest location in Strongsville later this winter. This will mark the eighth Aqua-Tots Swim School in Ohio, continuing the brand's mission to teach children everywhere how to become safe and confident swimmers for

Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025

(NASDAQ:RVPH), CUPERTINO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that the anti-inflammatory impacts of brilaroxazine from the Phase

The C3i Center welcomes Bobby Boursiquot as its new Vice President of Commercialization

MONTRÉAL, Nov. 12, 2025 (GLOBE NEWSWIRE) — The C3i Center is proud to announce the appointment of Bobby Boursiquot, B.Sc., MBA, as Vice President of Commercialization. With over two decades of experience in scientific innovation and commercial growth, Mr. Boursiquot will lead the C3i Center's initiatives to accelerate the transfer of cell and gene therapy

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

(NasdaqGM:KLRS), Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026 Recent significant corporate milestones include the selection of a

Scroll to Top